When Multiple Activists Circle the Same Stock: Wolf-Pack Filings in 2026

A wolf-pack filing is when two or more unaffiliated investors disclose Schedule 13D positions in the same issuer within a short window, short of forming a Section 13(d)(3) group. Of seven issuers carrying a 90-day cluster signal in the 13dwatch April 30, 2026 feed, three are true multi-activist wolf packs and four are single-filer amendment streams. Biotech accounts for four of seven.

The empirical baseline

Wolf-pack activism — a second filer arriving days after the first — is rarer than the headlines suggest. 13dwatch's /api/feed exposes a per-filing field called issuer_cluster.filings_in_window, which counts other Schedule 13D filings on the same issuer over a rolling 90-day window. In the April 30, 2026 feed, 11 of 60 filings (18.3%) carry a cluster value greater than one. Those 11 filings collapse to seven distinct issuers.

Filtering to filings where the second filer is a different reporting entity — the strict definition of a multi-activist event — leaves three issuers: Visium Technologies (NASDAQ: VISM), Alamar Biosciences (NASDAQ: ALMR), and Kailera Therapeutics (NASDAQ: KLRA). The Kailera case requires an asterisk: both filers are Bain Capital-affiliated funds.

Source: 13dwatch /api/feed, as-of 2026-04-30T12:13:19Z. Each filing links to its SEC EDGAR accession. The companion full-year aggregation lives in Every 2026 Schedule 13D Filing, Mapped.

Why the distinction between "cluster" and "wolf pack" matters

A multi-filing cluster captures any pair of Schedule 13D filings on the same issuer in a 90-day window. That includes a single filer amending its own position. The Securities and Exchange Commission (SEC) does not treat self-amendment as a coordinated event. Section 13(d)(3) of the Securities Exchange Act of 1934, codified at 15 U.S.C. § 78m(d)(3), defines a "group" as "two or more persons [who] act as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities." A group has joint reporting obligations and joint beneficial ownership. (For background on the form itself, see What Is a Schedule 13D Filing? and the comparison to 13G and 13F in 13D vs 13G vs 13F.)

What the academic literature calls a "wolf pack" sits below the group threshold. Coffee and Palia (2016) describe it as tacit coordination — one activist files the public Schedule 13D and other investors accumulate quietly, anticipating the campaign's price impact, without an explicit agreement. Brav, Dasgupta, and Mathews (2022) formalize the equilibrium: free-riders profit if the lead filer's campaign succeeds.

The SEC addressed this directly in its October 2023 final rule (Release No. 33-11253; effective February 5, 2024). The Commission declined to adopt a bright-line concerted-action rule but issued guidance that "two or more persons who 'act as' a group for purposes of acquiring, holding, or disposing securities may be treated as a group" — without a written agreement. Tacit coordination, in other words, is fact-specific and litigable.

What the three wolf packs actually look like

Visium Technologies (VISM): a deal-driven cluster, not adversarial activism

Two individuals filed Schedule 13Ds on Visium in late April 2026. Taylor Paul Richard disclosed a 3% stake on April 24, accession 0001654954-26-003904. Rai Cheddi Bharrat disclosed 12.1% on April 28, accession 0001654954-26-004008. Both filings reference Visium's "proposed acquisition of ConnexUs AI." Bharrat's filing states he expects to serve as Visium's Chief Operating Officer/Chief Technology Officer and a board member. This is a counterparty disclosure pattern — common when an issuer issues stock as deal consideration — not adversarial activism.

Alamar Biosciences (ALMR): two unaffiliated funds, same day

Same-day filings on April 23, 2026 by Illumina Innovation Fund II, L.P. (9.6%, accession 0001193125-26-173780) and Sands Capital Life Sciences Pulse Fund II, L.P. (6.3%, accession 0001875620-26-000007). Illumina's strategic-venture arm and Sands Capital's life-sciences fund have no disclosed coordination. Both filings cite "general investment purposes." The pattern fits the wolf-pack definition more cleanly than any other in the current feed.

Kailera Therapeutics (KLRA): same-parent affiliates

Same-day filings on April 23, 2026 by BCLS Fund IV Investments, L.P. (17.43%, with Adam Koppel of Bain Capital Life Sciences on the board) and BCPE Perseus Investor, LP (20.27%, with Andrew Kaplan of Bain Capital Private Equity on the board). Both filers are Bain Capital affiliates with separate investment committees and distinct board representation. Whether they constitute a Section 13(d)(3) group is fact-specific. Functionally, this is a sponsor-syndicate disclosure, not a true multi-activist event.

Sector pattern: biotech dominates

Of the seven cluster issuers, four are biotech (ACHV, ALMR, KLRA, GRTX). One is mining (NMG), one oil & gas (BATL), one micro-cap technology (VISM). Biotech accounts for 57% of multi-filing clusters in the recent feed.

The bias is structural, not a sentiment signal. Small-cap biotech issuers raise capital in PIPEs and follow-on offerings that frequently push individual investors above the 5% threshold. A clinical milestone — a Phase 2 readout, a partnership announcement, or a take-private rumor — can pull multiple specialized funds across the threshold within days. Industrial and energy issuers have stickier ownership and fewer threshold-crossing events.

The implication is that wolf-pack activism, in the strict adversarial sense, is concentrated outside biotech. Biotech "clusters" are typically capital-formation events, not campaign accumulation.

What this means for hedge fund analysts and RIAs

A naïve "two filers, 90 days" alert generates noise. The signal worth tracking is two unaffiliated activist filers, not capital-formation counterparties, with public Item 4 language indicating engagement intent. That filter, applied to the current feed, leaves Alamar Biosciences as the cleanest 2026-YTD example. The Item 4 disambiguation framework — what filer purpose statements actually disclose — is unpacked in How to Read Item 4 of a Schedule 13D.

For allocators, the operational question is: does your data feed surface the cluster, and does it let you separate true wolf packs from amendment streams and same-sponsor disclosures? 13dwatch's issuer_cluster field exposes the raw signal; the /api/feed endpoint is public.

Frequently Asked Questions

What is a wolf-pack filing in 13D activism?

A wolf-pack filing is the colloquial term for two or more unaffiliated activist investors disclosing Schedule 13D positions in the same issuer within a short window, without filing as a Section 13(d)(3) "group." The first filer's disclosure signals an emerging campaign; subsequent filers accumulate quietly and benefit from the lead filer's efforts. The pattern was formalized by Coffee and Palia (2016) and Brav et al. (2022).

Does a wolf pack have to file as a group under SEC rules?

Not automatically. A Section 13(d)(3) group exists when two or more persons "act as" a partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities. Tacit coordination short of an agreement is fact-specific. The SEC's October 2023 final rule clarified that "two or more persons who 'act as' a group... may be treated as a group" — without a written agreement — but declined to adopt a bright-line test.

How fast must a Schedule 13D be filed?

Under Rule 13d-1(a) as amended (effective February 5, 2024), the initial Schedule 13D must be filed within five business days after acquiring beneficial ownership of more than 5% of a covered class. Amendments under Rule 13d-2(a) must be filed within two business days after a material change.

How rare are true multi-activist clusters?

In the 13dwatch April 30, 2026 feed of 60 most-recent Schedule 13D and 13D/A filings, 11 filings carried a 90-day cluster signal, mapping to seven distinct issuers. Only three of the seven involved two unaffiliated reporting entities. Multi-activist clusters with three or more distinct filers within 90 days were not present in the feed.

Why is biotech overrepresented in 13D clusters?

Small-cap biotech issuers structurally produce more 5%-threshold events than industrial or energy issuers. PIPE financings, follow-on offerings, and clinical-milestone-driven trading can push multiple specialized funds across the threshold within days. The clustering signal in biotech often reflects capital-formation activity, not adversarial accumulation.

Where can I track multi-filer 13D clusters in real time?

The 13dwatch live feed surfaces the issuer_cluster.filings_in_window field on every filing. The full feed is available without authentication at /api/feed. Filings are joined to insider Form 4 transactions and FINRA short-interest data on the same view.

Methodology: This analysis uses 13dwatch's /api/feed endpoint, snapshot 2026-04-30T12:13:19Z. The endpoint returns the 60 most-recent Schedule 13D and 13D/A filings, enriched with insider activity, institutional consensus across 10 tracked portfolio managers, FINRA short interest, and a 90-day issuer cluster count. Cluster signal is computed against the full activist_filings table, not just the 60-row visible feed. Filings are linked to their EDGAR accessions for verification. Filer-affiliation determinations (Bain BCLS/BCPE) are based on filer-name matching against public sponsor disclosures. This is research, not investment advice. © 2026 Long Street Consulting LLC.

Track the next cluster as it forms — see the live feed at 13dwatch.com.